Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. IMMUNOCORE, LLC
EIR
•IMMUNOCORE, LLC•October 14, 2021

IMMUNOCORE, LLC – FDA EIR, Oct 14, 2021

Record Details

An FDA surveillance inspection of Immunocore LLC, located in Conshohocken, PA, was conducted from October 4 to October 14, 2021. This routine Prescription Drug User Fee (PDUFA) sponsor inspection, the company's first, aimed to assess Immunocore's oversight and responsibilities for clinical study IMCgp100-202, a Phase II study under NDA 114314. The inspection was performed in accordance with Compliance Program 7348.810 for Sponsors, Contract Research Organizations, and Monitors. A notable outcome of the inspection was that no Form FDA 483, Inspectional Observations, were issued, signifying compliance with regulatory standards. No refusals were encountered, and no samples were collected. The inspection comprehensively reviewed various aspects including organizational structures, standard operating procedures, vendor agreements, clinicaltrials.gov submissions, monitoring plans, and safety reporting mechanisms. While no formal violations were found, the report detailed an internal challenge at Site 6101 where a pharmacist initially resisted using a new drug formulation (IMCgp100, 0.2mg/ml) for several months. Immunocore’s clinical trial management team escalated and ultimately resolved this issue through direct intervention and training, leading to the formulation switch in March 2021. This demonstrates the sponsor's commitment to addressing operational issues. Immunocore exhibited robust oversight of its numerous outsourced services, including clinical investigator selection, site monitoring, data management, and pharmacovigilance, as evidenced by reviewed vendor management plans and regular communication protocols. Overall, the FDA inspection concluded without any regulatory findings, reflecting Immunocore's adherence to regulatory requirements for clinical trials.

Company
IMMUNOCORE, LLC
Inspection date
October 14, 2021
Product type
biologics
Office
Philadelphia District Office
Person
  • Stephanie C. Mangigian (investigator)
View Company Profile

ID · dfd49ad5-e105-4be2-9507-8be7805223ab

Violation Codes2
21 CFR 50.25(c)21 CFR 312

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore IMMUNOCORE, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.